MARY LABRIOLA: Open Payments
NPI 1124387659 · MONTGOMERY, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,018 in 168 payments from 29 companies in 2025. Trend: 2023 $2,173 · 2024 $2,799 · 2025 $3,018
Food & beverage: $3,018
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 17 | $449 |
| Novo Nordisk Inc | 16 | $306 |
| AstraZeneca Pharmaceuticals LP | 13 | $270 |
| PFIZER INC. | 14 | $269 |
| GlaxoSmithKline, LLC. | 12 | $214 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 12 | $177 |
| ABBVIE INC. | 14 | $177 |
| Amgen Inc. | 15 | $140 |
| Lilly USA, LLC | 8 | $121 |
| Otsuka America Pharmaceutical, Inc. | 5 | $116 |
Products named: INGREZZA, TRELEGY ELLIPTA, REXULTI, NURTEC ODT, Rybelsus, AIRSUPRA, MOUNJARO, Kerendia.
Industry payments across AL — which companies pay providers there.
